An antibody that immunospecifically binds folate receptor alpha for use in (a) a method for treating a FRA-expressing lung cancer in a patient, said method comprising: determining the patient's FRA expression level in a biological sample of the patient; comparing the patient's FRA expression level to a reference FRA expression level; and administering a therapeutically effective amount of said antibody to said patient if said patient's FRA expression level equals or exceeds said reference FRA expression level; or (b) a method for treating a FRA-expressing lung cancer in a patient, wherein the patient's FRA expression level equals or exceeds a reference FRA expression level; wherein said reference FRA expression level corresponds to the FRA expression level above which a patient population afflicted with said FRA-expressing lung cancer that is administered said antibody that immunospecifically binds FRA demonstrated a statistically significant improvement in at least one clinical outcome relative to a patient population afflicted with said FRA-expressing lung cancer that is administered placebo; wherein said reference FRA expression level is: (i) 42% +1 or greater anti-FRA staining; (ii) 21% +2 or greater anti-FRA staining; (iii) 14% +3 or greater staining; (iv) a FRAMSCOR of 7; or (v) a HBSCOR of 0.25; and wherein the antibody that immunospecifically binds FRA is: an antibody comprising SEQ ID NO:1 as CDRH1, SEQ ID NO:2 as CDRH2, SEQ ID NO:3 as CDRH3, SEQ ID NO:4 as CDRL1, SEQ ID NO:5 as CDRL2 and SEQ ID NO:6 as CDRL3; an antibody comprising a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:7 and/or a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 8; farletuzumab; an antibody that specifically binds to FRA comprising a mature light and heavy chain variable regions having at least 90% and preferably at least 95% or 99% sequence identity to SEQ ID NO: 7 and SEQ ID NO: 8, respectively; or an antibody or derivative thereof can competitively inhibit binding of farletuzumab to FRA, wherein the FRAMSCOR (M-score) is calculated as a weighted average, assuming a 0, 1+, 2+, 3+ scoring system as follows: x = % tumor stained at 1+ y = % tumor stained at 2+ z = % tumor stained at 3+, then M = x + 2 ⁢ y + 3 ⁢ z 6; and wherein the HBSCOR is derived from the sum of cell measurements (optical density) divided by the total number of cells. (a) a method for treating a FRA-expressing lung cancer in a patient, said method comprising: determining the patient's FRA expression level in a biological sample of the patient; comparing the patient's FRA expression level to a reference FRA expression level; and administering a therapeutically effective amount of said antibody to said patient if said patient's FRA expression level equals or exceeds said reference FRA expression level; or determining the patient's FRA expression level in a biological sample of the patient; comparing the patient's FRA expression level to a reference FRA expression level; and administering a therapeutically effective amount of said antibody to said patient if said patient's FRA expression level equals or exceeds said reference FRA expression level; or (b) a method for treating a FRA-expressing lung cancer in a patient, wherein the patient's FRA expression level equals or exceeds a reference FRA expression level; (i) 42% +1 or greater anti-FRA staining; (ii) 21% +2 or greater anti-FRA staining; (iii) 14% +3 or greater staining; (iv) a FRAMSCOR of 7; or (v) a HBSCOR of 0.25; an antibody comprising SEQ ID NO:1 as CDRH1, SEQ ID NO:2 as CDRH2, SEQ ID NO:3 as CDRH3, SEQ ID NO:4 as CDRL1, SEQ ID NO:5 as CDRL2 and SEQ ID NO:6 as CDRL3; an antibody comprising a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:7 and/or a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 8; farletuzumab; an antibody that specifically binds to FRA comprising a mature light and heavy chain variable regions having at least 90% and preferably at least 95% or 99% sequence identity to SEQ ID NO: 7 and SEQ ID NO: 8, respectively; or x = % tumor stained at 1+ y = % tumor stained at 2+ z = % tumor stained at 3+, then M = x + 2 ⁢ y + 3 ⁢ z 6; and wherein the HBSCOR is derived from the sum of cell measurements (optical density) divided by the total number of cells.